Association of PAI-1 serum levels and polymorphism of gene of Plasminogen Activator Inhibitor-1 in patient of Non-diabetic and Non-smoker with Coronary Artery Disease

Coronary Artery Disease (CAD) caused by atherosclerosis, Studies have shown that there are a number of factors which are closely related to the development and progression of CAD that include Cellular binding molecules like Plasminogen Activator Inhibitor-1 (PAI-1), multiple cardiac risk factors and hemostasis. In the present study we made an attempt to evaluate the association of PAI-1 4G/4G polymorphism and fibrinolysis markers example PAI-1 with CAD.
In this study, 140 individual, including 70 subjects as patient group and 70 subjects in the control group were considered. Blood samples were obtained from all participants, genomic DNA was extracted and the 4G/4G polymorphism of PAI-1 was amplified using specific primers. Polymorphism in the -675 position in promoter of PAI-1 was detected by PCR-RFLP method. Serum levels of PAI-1 in the samples were measured by ELISA.
Level of PAI-1 serum was significantly different between the two groups. PAI-1 genotype distribution in this case is the frequency of genotype 4G/4G in the patient group compared with the control group had higher. PAI-1 in patients who had genotype 4G, have a higher level compared to homozygous 5G (p-value=0.01). Significant differences between serum level of PAI-1 and PAI-1 gene polymorphism with the risk of CAD was observed.
The 4G/4G polymorphism of PAI-1 gene is a useful marker for fibrinolytic activity. This polymorphism due to increased in plasma level of PAI-1 which causes defects in fibrinolytic activity so increasing the occurrence of cardiovascular diseases.